LigoCyte Pharmaceuticals

About LigoCyte Pharmaceuticals

LigoCyte Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company established in 1998 in Bozeman, Montana. The firm specialized in developing vaccines for infectious diseases, particularly for gastrointestinal and respiratory indications. The company's core technology was its proprietary virus-like particle (VLP) platform. VLPs mimic the external structure of a virus without containing the genetic material required for replication, allowing the immune system to build defenses as if it were encountering the live virus.

LigoCyte's lead product candidate was a vaccine for norovirus, the most common cause of gastroenteritis outbreaks. This vaccine was the first to demonstrate protection against norovirus in human clinical trials and was in Phase I/II of development at the time of the company's acquisition. The company's pipeline also included preclinical development of vaccines for influenza, respiratory syncytial virus (RSV), and rotavirus. LigoCyte's development efforts were supported by a combination of private investment and grants from the National Institutes of Health (NIH) and the U.S. Department of Defense.

In October 2012, Takeda Pharmaceutical Company Limited, through its subsidiary Takeda America Holdings, Inc., acquired LigoCyte for an upfront payment of $60 million, with additional payments contingent on development milestones. The acquisition was a strategic move for Takeda to expand its global vaccine business, which had been launched in January 2012. Donald P. Beeman served as the CEO of LigoCyte at the time of the acquisition. Major investors in LigoCyte included Forward Ventures, Novartis Venture Fund, MedImmune Ventures, and GlaxoSmithKline, among others.